Twist Bioscience CAO awarded 16,324 RSUs, Form 4 filing reported

Twist Bioscience Corp (TWST) reported a Form 4 for its Chief Accounting Officer, Robert F. Werner.

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported a Form 4 for its Chief Accounting Officer, Robert F. Werner. On 11/18/2025, he received 16,324 shares of common stock through a restricted stock unit (RSU) award at a price of $0 per share, reflecting stock-based compensation rather than a market purchase.

After this grant, Werner beneficially owns 67,194 shares of Twist Bioscience common stock in direct ownership. The RSU award vests over time: 1/16 of the RSUs vest on each quarterly anniversary of November 20, 2024, for a total vesting period of 48 months, contingent on his continued service with the company.

Insider Trade Summary

Grant/Award: 16,324 shares

Grant/Award 1 txn

Insider WERNER ROBERT F.

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,324	$0.00	$0.00

Holdings After Transaction: Common Stock — 67,194 shares (Direct)

Footnotes (1)

1. F1. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2024 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.

FAQ

What insider transaction did Twist Bioscience (TWST) report in this Form 4?

The company reported that its Chief Accounting Officer, Robert F. Werner, received a grant of 16,324 RSUs of Twist Bioscience common stock on 11/18/2025.

How many Twist Bioscience (TWST) shares does the reporting person own after this transaction?

Following the RSU grant, Robert F. Werner beneficially owns 67,194 shares of Twist Bioscience common stock in direct ownership.

What are the vesting terms of the 16,324 RSUs reported for Twist Bioscience (TWST)?

The 16,324 RSUs vest so that 1/16 of the total vests on each quarterly anniversary of November 20, 2024, over a total of 48 months, subject to continuous service.

Did the Twist Bioscience (TWST) CAO pay cash for the RSUs in this Form 4?

No. The transaction shows 16,324 RSUs acquired at a price of $0 per share, indicating they were granted as equity compensation rather than purchased in the market.

What is the role of the reporting person in Twist Bioscience (TWST)?

The reporting person, Robert F. Werner, is an officer of Twist Bioscience serving as its Chief Accounting Officer.

Is this Form 4 for a single insider or a group at Twist Bioscience (TWST)?

This Form 4 is marked as “Form filed by One Reporting Person”, covering only the transactions of Robert F. Werner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WERNER ROBERT F.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		A		16,324(1)	A	$0	67,194	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2024 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.